M. Rodríguez-Torres

发表

Strong association of socioeconomic status with genetic ancestry in Latinos: implications for admixture studies of type 2 diabetes

D. Reich, M. Parra, G. Bedoya, 2009, Diabetologia.

Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population.

Amy L. Williams, T. Fennell, S. Gabriel, 2014, JAMA.

Treatment of HCV infection by targeting microRNA.

S. Kauppinen, S. Zeuzem, H. Janssen, 2013, The New England journal of medicine.

Sofosbuvir for previously untreated chronic hepatitis C infection.

John McNally, Michael Schultz, A. Mangia, 2013, The New England journal of medicine.

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

T. Ciuleanu, M. Rodríguez-Torres, I. Bondarenko, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Title Amerindian-specific regions under positive selection harbour new lipid variants in Latinos Permalink

T. Lehtimäki, R. Cantor, V. Salomaa, 2014 .

A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects

R. Hamatake, Z. Hong, M. Rodríguez-Torres, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

O. Weiland, P. Thuluvath, G. Everson, 2014, Gut.

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

D. Nelson, M. Rodríguez-Torres, E. Pulkstenis, 2010, Gastroenterology.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

E. Schiff, G. Everson, K. Kowdley, 2013, The New England journal of medicine.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

K. Reddy, T. Hassanein, D. Dieterich, 2013, The Lancet. Infectious diseases.

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

A. Lok, K. Reddy, P. Thuluvath, 2012 .

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16‐week abbreviated course of peginterferon alfa‐2a (40KD) plus ribavirin

S. Zeuzem, D. Nelson, M. Shiffman, 2010, Hepatology.

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.

P. Marcellin, P. Thuluvath, G. Everson, 2014, Gastroenterology.

Final results of a double‐blind, placebo‐controlled trial of the antifibrotic efficacy of interferon‐γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

K. Reddy, R. Gish, Z. Goodman, 2007, Hepatology.